文献速递精神分裂症与精神病性障碍

未治疗精神病患者脑脂肪酸酰胺水解酶显像研究

Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis.
PubMed 文献 · Biol Psychiatry · 2020-03-12

本研究采用新型FAAH放射性配体[11C]CURB对27例精神分裂症谱系障碍患者和36名健康对照进行PET扫描,发现患者与对照的FAAH水平无显著差异,但较低FAAH预测更严重的阳性精神病症状,且与较短病程和较长未治疗精神病时长相关。

要点

  • 精神病患者与健康对照的脑FAAH水平无显著差异。
  • 较低FAAH预测更严重的阳性精神病症状,效应量大。
  • 较短病程和较长未治疗精神病时长预测较低FAAH。

核心结论

  • 脑FAAH可能作为精神病疾病状态的生物标志物,并可能成为治疗阳性症状的新靶点。

研究设计与样本

  • 研究纳入27例精神分裂症谱系障碍患者和36名健康对照,完成高分辨率[11C]CURB PET扫描和结构磁共振成像,采用不可逆两组织室模型和代谢校正动脉输入函数分析数据。

主要发现

  • 患者与健康对照的FAAH无显著差异(F1,62.85=0.48,p=.49)。
  • 较低FAAH预测更严重的阳性精神病症状维度(F1,26.69=12.42,p=.002;Cohen's f=0.42,效应量大)。
  • 较短病程(F1,26.95=13.78,p=.001;Cohen's f=0.39,中到大效应)和较长未治疗精神病时长(F1,26.95=6.03,p=.021,Cohen's f=0.27,中等效应)预测较低FAAH。
  • FAAH在不同脑区存在显著差异(F7,112.62=175.85,p<1×10-56;Cohen's f>1),且女性总体FAAH高于男性(F1,62.84=10.05,p=.002;Cohen's f=0.37)。
  • 上述结果不能由既往大麻暴露或当前抗精神病药物摄入解释。

临床怎么用

  • 脑FAAH可能作为精神病疾病状态的生物标志物,用于靶向阳性症状的临床研究或作为治疗阳性症状的新干预靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The brain's endocannabinoid system, the primary target of cannabis, has been implicated in psychosis. The endocannabinoid anandamide is elevated in cerebrospinal fluid of patients with schizophrenia. Fatty acid amide hydrolase (FAAH) controls brain anandamide levels; however, it is unknown if FAAH is altered in vivo in psychosis or related to positive psychotic symptoms. METHODS: Twenty-seven patients with schizophrenia spectrum disorders and 36 healthy control subjects completed high-resolution positron emission tomography scans with the novel FAAH radioligand [11C]CURB and structural magnetic resonance imaging. Data were analyzed using the validated irreversible 2-tissue compartment model with a metabolite-corrected arterial input function. RESULTS: FAAH did not differ significantly between patients with psychotic disorders and healthy control subjects (F1,62.85 = 0.48, p = .49). In contrast, lower FAAH predicted greater positive psychotic symptom severity, with the strongest effect observed for the positive symptom dimension, which includes suspiciousness, delusions, unusual thought content, and hallucinations (F1,26.69 = 12.42, p = .002; Cohen's f = 0.42, large effect). Shorter duration of illness (F1,26.95 = 13.78, p = .001; Cohen's f = 0.39, medium to large effect) and duration of untreated psychosis predicted lower FAAH (F1,26.95 = 6.03, p = .021, Cohen's f = 0.27, medium effect). These results were not explained by past cannabis exposure or current intake of antipsychotic medications. FAAH exhibited marked differences across brain regions (F7,112.62 = 175.85, p < 1 × 10-56; Cohen's f > 1). Overall, FAAH was higher in female subjects than in male subjects (F1,62.84 = 10.05, p = .002; Cohen's f = 0.37). CONCLUSIONS: This first study of brain FAAH in psychosis indicates that FAAH may represent a biomarker of disease state of potential utility for clinical studies targeting psychotic symptoms or as a novel target for interventions to treat psychotic symptoms.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Watts JJ, Jacobson MR, Lalang N, et al. Imaging Brain Fatty Acid Amide Hydrolase in Untreated Patients With Psychosis. Biol Psychiatry. 2020. PMID: 32387132. doi:10.1016/j.biopsych.2020.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。